Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bentracimab Phase 2B Reversal of Ticagrelor
NCT04122170Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2019
- Primary completion
- Sep 2021
- Countries
- 2
- Sponsor
- SFJ Pharmaceuticals
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Drugs
- bentracimab
- Conditions
- hemorrhage
01
Overview
Phase 2, randomised, double-blind trial in hemorrhage comparing Bentracimab with Placebo (2 arms). Primary endpoint: Minimum Percent Inhibition of Platelet Reactivity Unit (PRU) Assessed by VerifyNow at 4 hours. Started Sep 2019; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Bentracimab
Bentracimab IV Infusion + Standard Care Background (Ticagrelor/ASA)
Placebo
Placebo IV Infusion + Standard Care Background (Ticagrelor/ASA)
03
Who it enrols
Healthy volunteers aged 50-80 years willing to take ticagrelor and aspirin pretreatment.
04
Endpoints
Primary
Minimum Percent Inhibition of Platelet Reactivity Unit (PRU) Assessed by VerifyNow
Beyond the preview
Go deeper on NCT04122170.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122170.